-
Mashup Score: 588Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study - 7 day(s) ago
Molnupiravir treatment in immunocompromised patients led to the accumulation of a distinctive pattern of mutations beyond the recommended 5 days of treatment. Treated patients maintained persistent PCR positivity for the duration of monitoring, indicating clear potential for transmission and subsequent emergence of novel variants.
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1403
The SARS-CoV-2 variant JN.1 swiftly became the global dominant strain1,2 due to a spike protein Leu455Ser substitution, boosting transmissibility and immune-escape capabilities, surpassing its predecessor BA.2.86 and other variants.1,3,4 These alterations have resulted in a surge of COVID-19 cases, reflected in wastewater-surveillance data surpassing rates, observed during the initial omicron wave. However, concerns persist that JN.1 might have an increased capacity to replicate in the gut, potentially leading to infected individuals shedding a higher number of viral copies than previously seen.
Source: www.thelancet.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 1AI-guided pipeline for proteinโprotein interaction drug discovery identifies a SARS-CoV-2 inhibitor | Molecular Systems Biology - 10 day(s) ago
imageimageA new pipeline for prioritizing protein-protein interactions (PPIs) for drug discovery, combines machine learning-based scoring of quantitative PPI data, protein complex structure prediction and virtual drug screening. A multi-adaptive …
Source: www.embopress.orgCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 5Hybrid immunity and SARS-CoV-2 antibodies: results of the HEROES-RECOVER prospective cohort study - 13 day(s) ago
In this cohort of 5,793 adults, hybrid immunity elicited superior antibody response compared to vaccination-only, however, this superiority was not repeated aft
Source: academic.oup.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 3864The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications - 13 day(s) ago
Objective To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications. Methods We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods. Each stage included all individuals eligible for vaccination, with no previous SARS-CoV-2 infection or COVID-19 vaccine at the start date. Vaccination status was used as a time-varying exposure. Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0โ30, 31โ90, 91โ180 and 181โ365โdays. Propensity score overlap weighting and empirical calibration were used to minimise observed and unobserved confounding, respectively. Fine-Gray models estimated subdistribution hazard ratios (sHR). Random effect meta-analyses were
Source: heart.bmj.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 481
The envelope protein is highly conserved among human coronaviruses, suggesting it could be a good drug target. Here, the authors develop a platform for the identification and optimization of peptides targeting the coronavirus envelope, and show that iPep-SARS2-E inhibits SARS-CoV-2 infection in lung organoids and in mice.
Source: journals.plos.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 3822The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications - 16 day(s) ago
Objective To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications. Methods We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods. Each stage included all individuals eligible for vaccination, with no previous SARS-CoV-2 infection or COVID-19 vaccine at the start date. Vaccination status was used as a time-varying exposure. Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0โ30, 31โ90, 91โ180 and 181โ365โdays. Propensity score overlap weighting and empirical calibration were used to minimise observed and unobserved confounding, respectively. Fine-Gray models estimated subdistribution hazard ratios (sHR). Random effect meta-analyses were
Source: heart.bmj.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 646An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations - 16 day(s) ago
ML2006a4 has improved affinity for SARS-CoV-2 Mpro and reduced sensitivity to mutations conferring resistance to nirmatrelvir or ensitrelvir.
Source: www.science.orgCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 3752The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications - 16 day(s) ago
Objective To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications. Methods We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods. Each stage included all individuals eligible for vaccination, with no previous SARS-CoV-2 infection or COVID-19 vaccine at the start date. Vaccination status was used as a time-varying exposure. Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0โ30, 31โ90, 91โ180 and 181โ365โdays. Propensity score overlap weighting and empirical calibration were used to minimise observed and unobserved confounding, respectively. Fine-Gray models estimated subdistribution hazard ratios (sHR). Random effect meta-analyses were
Source: heart.bmj.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 3752The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications - 17 day(s) ago
Objective To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications. Methods We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods. Each stage included all individuals eligible for vaccination, with no previous SARS-CoV-2 infection or COVID-19 vaccine at the start date. Vaccination status was used as a time-varying exposure. Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0โ30, 31โ90, 91โ180 and 181โ365โdays. Propensity score overlap weighting and empirical calibration were used to minimise observed and unobserved confounding, respectively. Fine-Gray models estimated subdistribution hazard ratios (sHR). Random effect meta-analyses were
Source: heart.bmj.comCategories: General Medicine News, Expert PicksTweet
Molnupiravir, a drug that relies on mutagenesis of #SARSCoV2 to work, is especially dangerous in people who are immunocompromised d/t accelerated evolution and potential transmission of mutated virus https://t.co/JwmaIC3y8Z @LancetMicrobe @nfountainjones cc @LongDesertTrain https://t.co/C5ruwgzPKb